Page 1,658«..1020..1,6571,6581,6591,660..1,6701,680..»

New Ocrevus Findings Show Benefits to Range of MS Patients: Interview with Genentech’s Dr. Hideki Garren – Multiple Sclerosis News Today

Posted: Published on July 7th, 2017

Genentechshared new insights into the workings of Ocrevus (ocrelizumab) and its effectiveness in reducing disease activity and slowing progression in relapsing and primary progressive multiple sclerosis (MS) at the recent3rd Congress of the European Academy of Neurology (EAN). The new findings, previously reported here, built on analyses of information gathered during the three Phase 3 clinical trialsassessing Ocrevus safety and efficacy, as well as throughmonitoring patients in extension studies. To better understand thisnew datas relevance to the patient community, Multiple Sclerosis News Today turned to Dr. Hideki Garren, group medical director of ocrelizumab at Genentech. One of the issues researchers evaluated in-depth at the congresswas NEPAD, short for No Evidence of Progression or Active Disease, a new measure of treatment efficacy used in the trials. NEPAD is a composite measure, similar to NEDA (No Evidence of Disease Activity), but it holds additional information. To achieve NEDA, an MS patient must have no relapses, no new or enhancing brain lesions on magnetic resonance imaging (MRI), and no disability progression assessed by the Expanded Disability Status Scale (EDSS). To fulfill NEPAD, all the requirements of NEDA must be met, plusnoconfirmed disability progression equal to or above 20% on a timed 25-foot walk … Continue reading

Posted in MS Treatment | Comments Off on New Ocrevus Findings Show Benefits to Range of MS Patients: Interview with Genentech’s Dr. Hideki Garren – Multiple Sclerosis News Today

Arena Upgraded, Analyst Sees 44% Upside – Benzinga

Posted: Published on July 7th, 2017

With phase 2 results expected to be released in the near future, JMP analyst Jason Butler upgraded his rating on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Market Outperform with a $27 price target. We believe the stocks current valuation under-appreciates the potential for clinical and commercial success of either of these assets (Ralinepag in pulmonary arterial hypertension and strasimod in ulcerative colitis), Butler said. Ralinepag has demonstrated a superior preclinical profile to selexipag. Preclinical and early clinical studies have shown that ralinepag has the potential to be the best-in-class oral prostacyclin agonist. The drug is more potent than other oral nonprostanoid prostacyclin receptor agonists and has a superior pharmacokinetic profile, including lower Cmax, reduced peak-to-trough ratio and potential for once-daily dosing, Butler noted. This pushed Butler to believe ralinepag could be the best oral prostacyclin agonist for the treatment of pulmonary arterial hypertension. Arena has a couple of other strong assets in its portfolio. Specifically, Butler highlighted Etrasimod, which he sees Arena accelerating its time to market. We believe Arenas focus on these orphan indications for etrasimod can accelerate development timelines and provide a differentiated commercial opportunity vs. other S1P1 modulators. He also stated how Axovant Sciences Ltd (NYSE: AXON) … Continue reading

Posted in Ulcerative Colitis | Comments Off on Arena Upgraded, Analyst Sees 44% Upside – Benzinga

Medical marijuana can treat Parkinson’s – LancasterOnline

Posted: Published on July 7th, 2017

As a nurse manager at a local nursing facility and a Millersville University nursing student, I want to express the importance of the introduction of medical marijuana as a treatment option for people suffering with Parkinsons disease. With the recent granting of 12 medical marijuana permits in Pennsylvania, the possibility of using this alternative therapy may be approaching. A handful of states already approved medical marijuana as a complimentary therapy in the treatment of Parkinsons. Parkinsons disease is a disorder of the brain that causes tremors and stiffness in muscles. This is a progressive disease for which there is no cure. Many of my patients have Parkinsons and suffer with tremors, pain and contracted muscles. They are unable to care for themselves or communicate. For my patients, there are very few treatment options, and much of my time is spent managing their symptoms. Many medications now approved for the treatment of Parkinsons only help to improve some of the symptoms and do not slow progression of the disease at all. A study done in Colorado in 2014 concluded that more than 70 percent of participants using medical marijuana to treat Parkinsons disease reported an improvement in their symptoms. There are … Continue reading

Posted in Parkinson's Treatment | Comments Off on Medical marijuana can treat Parkinson’s – LancasterOnline

New tool could lead to earlier diagnosis, better treatment of … – Medical Xpress

Posted: Published on July 7th, 2017

July 6, 2017 by Dov Smith Immunohistochemistry for alpha-synuclein showing positive staining (brown) of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia Parkinson's disease is the second most common neurodegenerative disorder in humans, after Alzheimer's disease. It is typically characterized by changes in motor control such as tremors and shaking, but can also include non-motor symptoms, from the cognitive to the behavioral. An estimated seven to 10 million people worldwide are living with Parkinson's disease, with medication costing approximately $2,500 a year, and therapeutic surgery costing up to $100,000 dollars, per patient. Making an accurate diagnosis of Parkinson's, particularly in early stages and mild cases, is difficult, and there are currently no standard diagnostic tests other than clinical information provided by the patient and the findings of a neurological exam. One of the best hopes for improving diagnosis is to develop a reliable test for identifying a biomarker, i.e. a substance whose presence would indicate the presence of the disease. Now, Suaad Abd-Elhadi, a PhD student at the Institute for Medical Research Israel-Canada (IMRIC) in the Hebrew University of Jerusalem's Faculty of Medicine, has developed the lipid ELISA. This novel diagnostic tool could lead to earlier … Continue reading

Posted in Parkinson's Treatment | Comments Off on New tool could lead to earlier diagnosis, better treatment of … – Medical Xpress

Capricor Regains Rights to CAP-1002 as Janssen Ends Collaboration – Genetic Engineering & Biotechnology News

Posted: Published on July 7th, 2017

Duchenne Trial Top-Line Results In April, Capricor reported more positive six-month top-line results from the Phase I/II Halt cardiomyOPathy progrEssion in Duchenne (HOPE-Duchenne) clinical trial, designed to assess the safety and preliminary efficacy of CAP-1002 in 25 subjects. Capricor cited statistically significant improvements in systolic thickening of the inferior wall of the heart and in the function of the middle and distal upper limb in CAP-1002 patients compared with control patients receiving usual care. The HOPE-Duchenne trial also found differences in several other cardiac and skeletal muscle measures, including cardiac scar, that Capricor said were consistent with a treatment effect. "Over the last few years, and during the term of the Janssen option period, we believe that significant value for our CAP-1002 asset has been created through the demonstration of clinical proof-of-concept to treat DMD, and also from the progress that has been made toward the development of a commercial-scale manufacturing process for the cells," Capricor president and CEO Linda Marbn, Ph.D., said in the statement. As a result, she said, Capricor will continue to develop CAP-1002, either alone or with a new collaboration partner. After announcing HOPE results, Capricor discussed potential product registration strategies for this indication at a … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Capricor Regains Rights to CAP-1002 as Janssen Ends Collaboration – Genetic Engineering & Biotechnology News

Private clinics’ peddling of unproven stem cell treatments is unsafe and unethical – Medical Xpress

Posted: Published on July 7th, 2017

July 7, 2017 by Megan Munsie And John Rasko, The Conversation Stem cells have saved thousands of lives thanks to their applications in cancer treatments. Many other uses peddled by private clinics are without evidence. Credit: http://www.shutterstock.com Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, are exploiting regulatory gaps to sell so-called stem cell treatments without evidence that what they offer is effective or even safe. Such unregulated direct-to-consumer advertising typically of cells obtained using liposuction-like methods not only places the health of individuals at risk, but could also undermine the legitimate development of stem cell-based therapies. Many academic societies and professional medical organisations have raised concerns about these futile and often expensive cell therapies. Despite this, national regulators have typically been slow or ineffective in curtailing them. As well as tighter regulations here, international regulators such as the World Health Organisation and the International Council on Harmonisation need to move on ensuring patients desperate for cures aren't sold treatments with limited efficacy and unknown safety. So what's on offer? Hundreds of … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Private clinics’ peddling of unproven stem cell treatments is unsafe and unethical – Medical Xpress

Stem cell therapies: medical experts call for strict international rules – The Guardian

Posted: Published on July 7th, 2017

Stem cells have long been used to treat blood cancers and some immune diseases. But some doctors are offering stem cell treatments for diseases still under clinical trial. Photograph: Mauricio Lima/AFP/Getty Images Medical and legal experts from around the world have united to call for more stringent regulation of stem cell therapies to prevent people pursuing unproven and potentially deadly treatments overseas. In a perspective piece for the US journal Science Translational Medicine, 15 experts from countries including the UK, the US, Canada, Belgium, Italy and Japan wrote that national efforts alone would not be enough to counter an industry offering unproven treatments to vulnerable patients. Stem cell-based interventions are classified under diverse and potentially incompatible national regulatory frameworks, the authors wrote. Approaches for international regulation not only need to develop consistent rules over the commercialisation of medical practices and products but also need to give them teeth by developing cross-border partnerships for compliance. Stem cells found in bone marrow and umbilical cord blood have long been used to successfully treat blood cancers including leukaemia and some immune diseases. But those are among the few proven treatments. Legitimate and ethics-approved clinical trials by academic centres are also occurring, exploring the … Continue reading

Posted in Stem Cell Research | Comments Off on Stem cell therapies: medical experts call for strict international rules – The Guardian

Colon Cancer-Driven Stem Cells Linked to High-Fat Diet – Genetic Engineering & Biotechnology News

Posted: Published on July 7th, 2017

Scientists in the U.S. have identified a molecular pathway that appears to play a key role in the link between a high-fat diet (HFD) and the development of colorectal cancer. The research, led by the Cleveland Clinics Sheerlarani Karunanithi, and Matthew Kalady, suggests that it may one day be possible to develop drugs that reduce tumor growth associated with obesity and a diet that is high in fat. Their research is published today, in Stem Cell Reports, in a paper titled, RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and MediatesHigh-Fat Diet-Induced Colon Carcinogenesis. The Cleveland Clinic teams review of published research indicated that high expression levels of two vitamin A signalling proteinsserum retinol binding protein (RPB4), stimulated by retinoic acid 6 (STRA6)in colorectal cancer tumors is associated with poor prognosis, increased tumor metastasis and recurrence, and resistance to cancer therapy. The RBP4-STRA6 pathway triggers the JAK2-STAT3 signaling cascade. The researchers engineered STRA6- or RBP4-knockdown cancer cells to demonstrate that the RBP4-STRA6 pathway is important for promoting cancer cell proliferation and survival and for maintaining the expression of core stem cell transcription factors. They also found that the RBP4-STRA6 pathway plays a key role in maintaining colon cancer stem cells (CSCs), … Continue reading

Posted in Stem Cell Research | Comments Off on Colon Cancer-Driven Stem Cells Linked to High-Fat Diet – Genetic Engineering & Biotechnology News

Private clinics’ peddling of unproven stem cell treatments is unsafe and unethical – The Conversation AU

Posted: Published on July 7th, 2017

Stem cells have saved thousands of lives thanks to their applications in cancer treatments. Many other uses peddled by private clinics are without evidence. Stem cell science is an area of medical research that continues to offer great promise. But as this weeks paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, are exploiting regulatory gaps to sell so-called stem cell treatments without evidence that what they offer is effective or even safe. Such unregulated direct-to-consumer advertising typically of cells obtained using liposuction-like methods not only places the health of individuals at risk, but could also undermine the legitimate development of stem cell-based therapies. Many academic societies and professional medical organisations have raised concerns about these futile and often expensive cell therapies. Despite this, national regulators have typically been slow or ineffective in curtailing them. As well as tighter regulations here, international regulators such as the World Health Organisation and the International Council on Harmonisation need to move on ensuring patients desperate for cures arent sold treatments with limited efficacy and unknown safety. Hundreds of stem cell clinics post online claims that they have been able to treat patients suffering from a … Continue reading

Posted in Stem Cell Research | Comments Off on Private clinics’ peddling of unproven stem cell treatments is unsafe and unethical – The Conversation AU

Medicaid vital to well-being of our children – Wichita Eagle (blog)

Posted: Published on July 7th, 2017

Medicaid vital to well-being of our children Wichita Eagle (blog) I am there for their developmental milestones and diagnosis and treatment of chronic conditions, and I am there to help families make difficult choices during trying moments. My practice in Kansas City, Kan., sees patients with all types of coverage ... and more » Read the rest here: Medicaid vital to well-being of our children - Wichita Eagle (blog) … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Medicaid vital to well-being of our children – Wichita Eagle (blog)

Page 1,658«..1020..1,6571,6581,6591,660..1,6701,680..»